

# Contents

Preface — v

Contributing authors — xiii

List of abbreviations — xv

Sriram Gopu and Cao Tong

## **1 Human pluripotent stem-cell-derived vascular cells: *in vitro* model for angiogenesis and drug discovery — 1**

- 1.1 Introduction — 1
- 1.2 Formation of blood vessels — 2
- 1.3 Current models to assess angiogenesis — 3
- 1.3.1 *In vitro* assays — 5
- 1.3.2 *In vivo* models of angiogenesis — 10
- 1.4 Promise of stem-cell-based angiogenesis models — 13
- 1.5 Differentiation of human PSCs into vascular lineages — 14
- 1.5.1 Embryoid body-mediated differentiation — 15
- 1.5.2 Co-culture mediated differentiation — 16
- 1.5.3 Directed vascular differentiation with specific factors and matrix components — 16
- 1.6 Building blood vessels *in vitro* – PSC models of angiogenesis — 20
- 1.6.1 2D co-culture angiogenesis assay — 20
- 1.6.2 Embryoid body-based 3D angiogenesis models — 22
- 1.6.3 3D vascular spheroidal co-culture model — 23
- 1.6.4 *In vitro* 3D vascularized tissue equivalent (vascular organoids) model — 25
- 1.7 Conclusions and future outlook — 26
- 1.8 References — 28

Irfan Khan, Nadia Naeem, Anwar Ali and Asmat Salim

## **2 Role of small molecules in the cardiac differentiation of mesenchymal stem cells — 35**

- 2.1 Introduction — 35
- 2.2 Epigenetic modifiers and cardiomyogenic differentiation of MSCs — 38
- 2.2.1 5-azacytidine — 40
- 2.2.2 Zebularine — 42
- 2.2.3 RG108 — 45
- 2.3 Cardioprotective compounds — 45
- 2.3.1 Statins — 45
- 2.3.2 Resveratrol — 48
- 2.3.3 Trimetazidine — 49

- 2.3.4 Pioglitazone — 49
- 2.4 Fatty acids and lipids — 50
- 2.4.1 Phorbol myristate acetate — 50
- 2.4.2 Sphingosine-1-phosphate — 50
- 2.5 Acids — 51
- 2.5.1 Salvianolic acid B — 51
- 2.5.2 Retinoic acid — 52
- 2.6 Peptides and peptide hormones — 52
- 2.6.1 Triiodo-L-thyronine — 52
- 2.6.2 Oxytocin — 52
- 2.6.3 Neuropeptide Y — 53
- 2.7 Miscellaneous compounds — 53
- 2.8 Conclusions — 54
- 2.9 References — 54

Dursun Gündüz and Muhammad Aslam

**3 MicroRNAs as modulators of endothelial differentiation of stem cells: role in vascular regenerative medicine — 63**

- 3.1 Introduction — 63
- 3.2 MicroRNAs — 64
- 3.3 Stem cells in vascular regeneration — 65
- 3.4 Endothelial enriched miRNAs and their role in angiogenesis — 66
- 3.4.1 miR-126 — 67
- 3.4.2 miR-17/92 cluster — 68
- 3.4.3 miR-15a/16 — 68
- 3.4.4 miR-130a — 69
- 3.4.5 miR-21 — 69
- 3.5 Post-ischemic collateral growth and miRNAs — 70
- 3.6 miRNAs regulating endothelial differentiation of EPCs and angiogenesis — 71
- 3.6.1 Role in proliferation — 71
- 3.6.2 Role in senescence — 72
- 3.6.3 Role in differentiation — 72
- 3.7 ESC-specific miRNAs regulating their commitment to ECs — 73
- 3.8 iPSCs and miRNAs — 76
- 3.9 Future applications and outlook — 77
- 3.10 References — 78

Sheikh Riazuddin, Azra Mehmood, Noreen Latief and Moazzam Nazeer Tarar

**4 Cells for the repair of damaged skin and cartilage — 85**

- 4.1 Introduction — 85
- 4.2 Stem cells in the repair of damaged skin — 86
- 4.2.1 Skin structure and function — 86

- 4.2.2 Skin diseases and injuries — 87
- 4.2.3 Conventional therapy of skin wounds — 87
- 4.2.4 Cellular therapy of skin wounds — 88
- 4.2.5 Skin bioengineering — 93
- 4.2.6 Stem cells for cosmetic purposes — 94
- 4.3 Stem cells for the repair of damaged cartilage — 94
- 4.3.1 Cartilage structure and function — 94
- 4.3.2 Diseases and injury to cartilage — 95
- 4.3.3 Approaches for repair of cartilage — 96
- 4.3.4 Repair of damaged cartilage by implantation of stem cells — 97
- 4.3.5 Transplantation of MSCs — 99
- 4.3.6 Scaffolds for cartilage repair — 101
- 4.4 Whether *in vitro* structures adequately meet *in vivo* functions? — 102
- 4.5 Future prospects of cell therapies — 102
- 4.6 References — 103

Mansour Saleh Alsharidah, Khawaja Husnain Haider, Elmuataz Elmansi Abdalla and Salman Afroze Azmi Mohammed

- 5 The skeletal muscle stem cells: biology and use in regenerative medicine — 111**
- 5.1 Introduction — 111
- 5.2 An overview of satellite cell markers — 112
- 5.3 The origin of satellite cells and their role in muscle repair and regeneration — 114
- 5.4 Isolation and culture of muscle stem cells — 116
- 5.5 Proliferation and differentiation of myogenic stem cells — 117
- 5.6 Skeletal muscle cells in regenerative therapy and drug development — 118
- 5.6.1 Satellite cells and SkMs for the treatment of muscular dystrophies — 118
- 5.6.2 Satellite cells and SkMs for the treatment of sphincter incontinence — 119
- 5.6.3 Satellite cells and SkMs for cardiomyopathies — 120
- 5.7 Conclusions — 122
- 5.8 References — 122

Changfa Guo, Kai Zhu and Khawaja Husnain Haider

- 6 Nanoparticle-based genetic engineering of mesenchymal stem cells — 129**
- 6.1 Introduction — 129
- 6.2 Genetic modification of MSCs — 130
- 6.3 Methods to genetically modify MSCs — 131

- 6.4 Exploiting nanoparticle technology for genetic priming of stem cells — **132**
- 6.5 Nanoparticle-based systems for gene transfer — **133**
  - 6.5.1 Polymer-based nanoparticles — **133**
  - 6.5.2 Inorganic nanoparticles — **135**
- 6.6 The mechanism of nanoparticle-based gene transfer — **136**
  - 6.6.1 Uptake pathways — **136**
  - 6.6.2 Endo-lysosomal escape — **137**
- 6.7 Factors influencing nanoparticle-based gene transfer — **137**
  - 6.7.1 Characteristics of nanoparticles as determinants of gene transfer efficiency — **137**
  - 6.7.2 Characteristics of cells as determinants of gene transfer efficiency — **139**
- 6.8 Recent advances and modifications in nanoparticle-based gene transfer — **140**
  - 6.8.1 Beacon-like modification — **140**
  - 6.8.2 Missile-like modification — **141**
- 6.9 Conclusions — **141**
- 6.10 References — **142**

Seyed Mojtaba Hosseini, Seyed Mohyeddin Ziaee and Parisa Tabeshmehr

- 7 Neural stem cells in regenerative medicine — 148**
  - 7.1 Introduction — **148**
  - 7.2 Chronology of events involving NSCs — **149**
  - 7.3 NSCs in embryonic period — **150**
  - 7.4 NSCs in adults — **151**
  - 7.5 Identification of the neural stem cells — **153**
  - 7.6 Regulation of NSCs — **155**
  - 7.7 Neurogenic niche microenvironment — **157**
  - 7.8 NSCs in cell-based therapy — **158**
    - 7.8.1 NSCs for cell-based therapy of Parkinson's disease — **158**
    - 7.8.2 NSCs for cell-based therapy of AD — **159**
    - 7.8.3 NSCs for cell-based therapy for spinal cord injury — **160**
    - 7.8.4 NSCs for cell-based therapy of stroke — **161**
  - 7.9 Conclusion — **162**
  - 7.10 References — **167**

Ye Lei and Khawaja Husnain Haider

- 8 "Paracrine" the heart with stem cells — 176**
  - 8.1 Introduction — **176**
  - 8.2 Overview of cell transplantation for cardiac repair — **177**
  - 8.3 Cellular cardiomyoplasty and paracrine factors — **179**

8.3.1	Skeletal myoblasts —	<b>179</b>
8.3.2	BM-derived stem cells —	<b>182</b>
8.3.3	Sca1 <sup>+</sup> /CD31 <sup>-</sup> cells —	<b>185</b>
8.3.4	c-Kit <sup>+</sup> cells —	<b>187</b>
8.3.5	Pluripotent stem cells derived cells —	<b>188</b>
8.4	Conclusion —	<b>190</b>
8.5	References —	<b>193</b>

<b>Index —</b>	<b>204</b>
----------------	------------

